---
title: "Treatment of Anorexia Nervosa in Children and Adolescents: An Integrated Family Based and Metacognitive Approach"
nct_id: NCT06139770
overall_status: ACTIVE_NOT_RECRUITING
phase: NA
sponsor: Norwegian University of Science and Technology
study_type: INTERVENTIONAL
primary_condition: Anorexia Nervosa
countries: Norway
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06139770.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06139770"
ct_last_update_post_date: 2025-06-22
last_seen_at: "2026-05-12T06:19:05.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Treatment of Anorexia Nervosa in Children and Adolescents: An Integrated Family Based and Metacognitive Approach

**Official Title:** Treatment of Anorexia Nervosa in Children and Adolescents: An Integrated Family-based and Metacognitive Approach

**NCT ID:** [NCT06139770](https://clinicaltrials.gov/study/NCT06139770)

## Key Facts

- **Status:** ACTIVE_NOT_RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 48
- **Lead Sponsor:** Norwegian University of Science and Technology
- **Collaborators:** St. Olavs Hospital
- **Conditions:** Anorexia Nervosa
- **Start Date:** 2023-11-01
- **Completion Date:** 2026-12-01
- **CT.gov Last Update:** 2025-06-22

## Brief Summary

The goal of this study is to evaluate the treatment effects of an integrated treatment called Family-based and Metacognitive therapy for patients with Anorexia Nervosa. In addition, we will evaluate if an active follow-up of the patients will reduce the number of relapses, which is common during the 1 year after discharge. Fifty patients aged 12-18 years old and their parents will be invited to participate in this study and all will receive the same treatment but be randomly allocated to different follow-up conditions. The active follow-up includes 3 sessions of Metacognitive therapy and the passive follow-up includes ordinary follow-up, with no booster sessions. The patients will be assessed at baseline, pre-treatment, post-treatment, and at 6 and 12 months follow-up.

## Detailed Description

The study is an evaluation of a new approach to treating Anorexia Nervosa (F.50.0 and F 50.1) called Family-based and Metacognitive therapy. The treatment integrates both family-based work approach, where the parents learn to be in control of the meal situation and communicate better with their child. The metacognitive treatment approach, is targeting the child to work with its problems with emotional regulation and self-esteem issues, but also their attitudes to body and weight. Our aim is to both address what the overall effect of the treatment will be, but also to test if an active follow-up after discharge will lead to reduced relapse rates in the 12 months after treatment. We will apply the same approach to all included patients (A-B design), but the patients and their parents will be allocated to one of two different conditions for follow-up. The active follow-up involves receiving 3 sessions of metacognitive therapy, whereas the other group gets ordinary follow-up, with no sessions of MCT. All patients are assessed at baseline, pre-treatment, post-treatment, and by 6 and 12 months follow-up. The purpose of the design is to evaluate if the rate of relapse during the first year after discharge can be reduced

## Eligibility

- **Minimum age:** 12 Years
- **Maximum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Primary diagnosis of F 50.0 and F 50.1

Exclusion Criteria:

* Psychotic symptoms
* Severe somatic illness
* Mental retardation or developmental disorder
* Bipolar disorder
* Extreme self-mutilation or acute suicidal risks
* Does not speak or understand Norwegian
```

## Arms

- **Active follow-up** (ACTIVE_COMPARATOR) — The patients will recieve 3 sessions of MCT
- **Passive follow-up** (ACTIVE_COMPARATOR) — The group receives no sessions during follow-up

## Interventions

- **Family based therapy- Metacognitive therapy** (BEHAVIORAL) — Family based therapy and Metacognitive therapy

## Primary Outcomes

- **Body Mass Index** _(time frame: 18 months)_ — Body mass index

## Locations (1)

- St.Olavs hospital HF, Trondheim, Trøndelag, Norway

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.st.olavs hospital hf|trondheim|trøndelag|norway` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06139770.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06139770*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*